Stay updated on Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Sign up to get notified when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The site version was updated from v3.4.3 to v3.5.0; no visible content changes were introduced.
    Difference
    0.0%
    Check dated 2026-03-25T20:40:19.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Hepatocellular Carcinoma is now listed under Conditions and a Resources section with the Genetic and Rare Diseases Information Center has been added.
    Difference
    0.1%
    Check dated 2026-03-18T14:53:32.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    - Revision updated from v3.4.2 to v3.4.3. This appears to be a minor internal update with no user-facing changes to the Study Details page.
    Difference
    0.0%
    Check dated 2026-03-11T15:55:44.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Cosmetic UI/Layout changes observed with no modification to core study details or outcomes.
    Difference
    0.0%
    Check dated 2026-03-04T11:51:11.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    A new Revision: v3.4.2 tag was added. A non-critical funding/operating status notice was removed; core trial content and page functionality remain unchanged.
    Difference
    0.2%
    Check dated 2026-02-11T02:35:20.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding and NIH operating status was added, and the site revision was updated from 3.4.0 to 3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-02-03T23:53:23.000Z thumbnail image

Stay in the know with updates to Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.